Serveur d'exploration sur la musique en Sarre

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The mechanisms of thrombotic risk induced by hormone replacement therapy

Identifieur interne : 000D09 ( Main/Exploration ); précédent : 000D08; suivant : 000D10

The mechanisms of thrombotic risk induced by hormone replacement therapy

Auteurs : Antonio Cano [Espagne] ; W. Marchien Van Baal [Pays-Bas]

Source :

RBID : ISTEX:5BBEB204B98AA5FDF54122FD632D6DE1B1ACFD31

Descripteurs français

English descriptors

Abstract

Objective: To review the available information on the action of hormones on the mechanisms involved in thrombotic risk. Results and Conclusions: Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemostatic balance, the coagulation cascade, the anticoagulant system and fibrinolysis, to oestrogens has been widely examined in the literature. Functional tests suggest that HRT is accompanied by a procoagulant state. Much of the work has concentrated on changes induced on reputable indicators of risk for either CHD or VTED. Distinct indicators of increased coagulability, such as resistance to activated C protein, antithrombin or tissue factor pathway inhibitor have been selected for VTED, whereas factor VII, fibrinogen, and defective fibrinolysis, for CHD. Different states of genetic susceptibility have been involved in both forms of the disease. The status of health of endothelium, defines another scenario for attention in CHD. A long-term anti-atherogenic action of oestrogens, which may be associated with short-term risk in cases of atherosclerosis-induced endothelial dysfunction, may most adequately explain much of the clinical observation. In both CHD and VTED, the procoagulant changes initiate soon after HRT administration.

Url:
DOI: 10.1016/S0378-5122(01)00270-5


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The mechanisms of thrombotic risk induced by hormone replacement therapy</title>
<author>
<name sortKey="Cano, Antonio" sort="Cano, Antonio" uniqKey="Cano A" first="Antonio" last="Cano">Antonio Cano</name>
</author>
<author>
<name sortKey="Van Baal, W Marchien" sort="Van Baal, W Marchien" uniqKey="Van Baal W" first="W. Marchien" last="Van Baal">W. Marchien Van Baal</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5BBEB204B98AA5FDF54122FD632D6DE1B1ACFD31</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1016/S0378-5122(01)00270-5</idno>
<idno type="url">https://api.istex.fr/document/5BBEB204B98AA5FDF54122FD632D6DE1B1ACFD31/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000969</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000969</idno>
<idno type="wicri:Area/Istex/Curation">000919</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B00</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B00</idno>
<idno type="wicri:doubleKey">0378-5122:2001:Cano A:the:mechanisms:of</idno>
<idno type="wicri:Area/Main/Merge">000D10</idno>
<idno type="wicri:Area/Main/Curation">000D09</idno>
<idno type="wicri:Area/Main/Exploration">000D09</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">The mechanisms of thrombotic risk induced by hormone replacement therapy</title>
<author>
<name sortKey="Cano, Antonio" sort="Cano, Antonio" uniqKey="Cano A" first="Antonio" last="Cano">Antonio Cano</name>
<affiliation wicri:level="1">
<country wicri:rule="url">Espagne</country>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Pediatrics, Obstetrics and Gynecology, Faculty of Medicine and Dentistry, University of Valencia, Avda. Blasco Ibañez, 17, E 46010 Valencia</wicri:regionArea>
<placeName>
<region nuts="2" type="communauté">Communauté valencienne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Van Baal, W Marchien" sort="Van Baal, W Marchien" uniqKey="Van Baal W" first="W. Marchien" last="Van Baal">W. Marchien Van Baal</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Obstetrics and Gynecology, University Hospital Vrije Universiteit, Amsterdam</wicri:regionArea>
<placeName>
<settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Maturitas</title>
<title level="j" type="abbrev">MAT</title>
<idno type="ISSN">0378-5122</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="2001">2001</date>
<biblScope unit="volume">40</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="17">17</biblScope>
<biblScope unit="page" to="38">38</biblScope>
</imprint>
<idno type="ISSN">0378-5122</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0378-5122</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cardiovascular disease</term>
<term>Endothelium</term>
<term>HRT</term>
<term>Hemostasia</term>
<term>Menopause</term>
<term>Thrombosis</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Activator</term>
<term>Adhesion</term>
<term>Adhesion molecules</term>
<term>Aggregation</term>
<term>Anticoagulant</term>
<term>Anticoagulant system</term>
<term>Antithrombin</term>
<term>Arterioscler</term>
<term>Arterioscler thromb vasc biol</term>
<term>Atheromatous</term>
<term>Atheromatous plaques</term>
<term>Atherosclerosis</term>
<term>Baal</term>
<term>Baal maturitas</term>
<term>Biol</term>
<term>Brin</term>
<term>Brinogen</term>
<term>Brinolysis</term>
<term>Brinolytic</term>
<term>Brinolytic activity</term>
<term>Brinolytic system</term>
<term>Cano</term>
<term>Cardiovascular</term>
<term>Cardiovascular disease</term>
<term>Clin</term>
<term>Clinical events</term>
<term>Coagulation</term>
<term>Coagulation activation</term>
<term>Coagulation cascade</term>
<term>Contraceptive</term>
<term>Coronary artery disease</term>
<term>Coronary events</term>
<term>Coronary heart disease</term>
<term>Endothelial</term>
<term>Endothelial cells</term>
<term>Endothelial dysfunction</term>
<term>Endothelium</term>
<term>Engl</term>
<term>Estradiol</term>
<term>Estrogen</term>
<term>Estrogen replacement therapy</term>
<term>Fertil steril</term>
<term>Fibrinogen</term>
<term>Functional tests</term>
<term>Fvii</term>
<term>Fviii</term>
<term>Glycoprotein</term>
<term>Gynecol</term>
<term>Haemost</term>
<term>Hemostatic</term>
<term>Hemostatic balance</term>
<term>Hemostatic variables</term>
<term>High levels</term>
<term>High plasma concentrations</term>
<term>High prevalence</term>
<term>Hormone replacement therapy</term>
<term>Infarction</term>
<term>Inhibitor</term>
<term>Lancet</term>
<term>Leiden</term>
<term>Lipoprotein</term>
<term>Maturitas</term>
<term>Menopausal status</term>
<term>Menopause</term>
<term>Mutation</term>
<term>Myocardial infarction</term>
<term>Northwick park heart study</term>
<term>Obstet</term>
<term>Obstet gynecol</term>
<term>Oestrogen</term>
<term>Oral contraceptives</term>
<term>Oral oestrogens</term>
<term>Pathway</term>
<term>Pepi trial</term>
<term>Plaque</term>
<term>Plasma levels</term>
<term>Plasmin</term>
<term>Plasminogen</term>
<term>Plasminogen activator</term>
<term>Plasminogen activator inhibitor type</term>
<term>Platelet</term>
<term>Platelet aggregation</term>
<term>Postmenopausal</term>
<term>Postmenopausal women</term>
<term>Proc natl acad</term>
<term>Procoagulant</term>
<term>Progestogen</term>
<term>Progression</term>
<term>Prothrombin</term>
<term>Prothrombin gene</term>
<term>Prothrombotic</term>
<term>Randomised</term>
<term>Risk factor</term>
<term>Risk factors</term>
<term>Rosendaal</term>
<term>Secondary prevention</term>
<term>Shear stress</term>
<term>Stampfer</term>
<term>Susceptibility states</term>
<term>Thromb</term>
<term>Thromb haemost</term>
<term>Thrombin</term>
<term>Thrombin generation</term>
<term>Thromboembolic</term>
<term>Thromboembolism</term>
<term>Thrombosis</term>
<term>Thrombotic</term>
<term>Thrombotic risk</term>
<term>Thrombus</term>
<term>Transdermal</term>
<term>Transdermal estradiol</term>
<term>Vasc</term>
<term>Vascular</term>
<term>Vascular wall</term>
<term>Venous</term>
<term>Venous thromboembolic disease</term>
<term>Venous thromboembolism</term>
<term>Venous thrombosis</term>
<term>Venous tree</term>
<term>Vessel wall</term>
<term>Vted</term>
<term>Willebrand factor</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Maladie cardio-vasculaire</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Objective: To review the available information on the action of hormones on the mechanisms involved in thrombotic risk. Results and Conclusions: Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemostatic balance, the coagulation cascade, the anticoagulant system and fibrinolysis, to oestrogens has been widely examined in the literature. Functional tests suggest that HRT is accompanied by a procoagulant state. Much of the work has concentrated on changes induced on reputable indicators of risk for either CHD or VTED. Distinct indicators of increased coagulability, such as resistance to activated C protein, antithrombin or tissue factor pathway inhibitor have been selected for VTED, whereas factor VII, fibrinogen, and defective fibrinolysis, for CHD. Different states of genetic susceptibility have been involved in both forms of the disease. The status of health of endothelium, defines another scenario for attention in CHD. A long-term anti-atherogenic action of oestrogens, which may be associated with short-term risk in cases of atherosclerosis-induced endothelial dysfunction, may most adequately explain much of the clinical observation. In both CHD and VTED, the procoagulant changes initiate soon after HRT administration.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Espagne</li>
<li>Pays-Bas</li>
</country>
<region>
<li>Communauté valencienne</li>
<li>Hollande-Septentrionale</li>
</region>
<settlement>
<li>Amsterdam</li>
</settlement>
</list>
<tree>
<country name="Espagne">
<noRegion>
<name sortKey="Cano, Antonio" sort="Cano, Antonio" uniqKey="Cano A" first="Antonio" last="Cano">Antonio Cano</name>
</noRegion>
<name sortKey="Cano, Antonio" sort="Cano, Antonio" uniqKey="Cano A" first="Antonio" last="Cano">Antonio Cano</name>
</country>
<country name="Pays-Bas">
<region name="Hollande-Septentrionale">
<name sortKey="Van Baal, W Marchien" sort="Van Baal, W Marchien" uniqKey="Van Baal W" first="W. Marchien" last="Van Baal">W. Marchien Van Baal</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sarre/explor/MusicSarreV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D09 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D09 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sarre
   |area=    MusicSarreV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:5BBEB204B98AA5FDF54122FD632D6DE1B1ACFD31
   |texte=   The mechanisms of thrombotic risk induced by hormone replacement therapy
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Sun Jul 15 18:16:09 2018. Site generation: Tue Mar 5 19:21:25 2024